Business Context and Reporting Period
Company: Altimmune, Inc. (ALT)
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2025
Primary Event: Announcement of topline 48-week data from the IMPACT Phase 2b clinical trial for pemvidutide, a dual glucagon/GLP-1 receptor agonist for metabolic dysfunction-associated steatohepatitis (MASH).
Key Financial Metrics and Liquidity
This filing does not contain a full set of financial statements (Revenue, Net Income, or Cash Flow). However, it discloses specific capital raising activity:
- ATM Program Activity: Between September 30, 2025, and December 19, 2025, the Company sold 13,547,341 shares of common stock under its Equity Distribution Agreements.
- Net Proceeds: Approximately $54.6 million.
- ATM Capacity: A new agreement with Leerink Partners LLC allows for up to $200.0 million in aggregate offering price.
Note: The filing text does not provide a clear value for total cash on hand, total debt, or operating margins.
Material Changes and Clinical Results
The primary material change is the positive 48-week topline data for pemvidutide in the IMPACT Phase 2b trial (NCT05989711) involving 212 participants with biopsy-confirmed MASH (F2/F3 fibrosis). Key results versus placebo include:
- Fibrosis Markers: Statistically significant reductions in Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM).
- ELF reduction: -0.49 (1.2 mg) and -0.58 (1.8 mg) vs. +0.16 (placebo).
- LSM reduction: -3.04 (1.2 mg) and -3.97 (1.8 mg) vs. -0.03 (placebo).
- Liver Health & Inflammation: Significant reductions in liver fat content (45.2% and 54.7% vs. 8.2%), ALT levels, and corrected T1 (cT1).
- Weight Loss: 4.5% (1.2 mg) and 7.5% (1.8 mg) vs. 0.2% (placebo), with no plateauing observed at 48 weeks for the 1.8 mg dose.
- Safety: Discontinuation due to adverse events was 0% (1.2 mg) and 1.2% (1.8 mg) vs. 3.5% (placebo). No serious or severe treatment-related adverse events were reported.
Guidance, Outlook, and Regulatory Status
- FDA Engagement: An End-of-Phase 2 meeting was held on December 11, 2025. The FDA indicated openness to using AIM-MASH AI Assist (an FDA-qualified AI pathology tool) for future trials.
- Phase 3 Pathway: The Company intends to evaluate multiple doses, including 2.4 mg, for a registrational Phase 3 trial in moderate to advanced fibrosis. Final meeting minutes are expected in January 2026.
- Regulatory Strategy: The Company is seeking scientific advice from European regulators to inform the final Phase 3 protocol.
- Risks: Forward-looking statements are subject to risks regarding clinical trial success, regulatory approvals, manufacturing timelines, and the Company's ability to fund operations.
Investor Verification Checklist
- Verify the final minutes of the December 11, 2025, FDA End-of-Phase 2 meeting expected in January 2026.
- Confirm the specific Phase 3 trial design, including the inclusion of the 2.4 mg dose and the use of AIM-MASH AI Assist.
- Monitor the remaining capacity and execution of the $200 million ATM program with Leerink Partners.
- Review the full clinical study report to understand the histological endpoints (MASH resolution/fibrosis improvement) which were primary endpoints at 24 weeks but are not detailed in this topline summary.
- Assess the Company's cash runway given the capital-intensive nature of Phase 3 trials and the recent $54.6 million raise.